AstraZeneca moved to strengthen its core oncology business on Tuesday with three deals designed to expand the British drugmaker's reach in treating tumors.
MedImmune
Breaking News
AstraZeneca's MedImmune unit has partnered with Immunocore, a private British biotechnology company, to develop a cancer drug that would tap on the body's immune system, Reuters reported.
Subscribe to VCpost newsletter
Most Popular
- Doctors Raise Concerns Over Proposed Capital Gains Tax Changes
- Celebrity Designer Nancy Gonzalez Jailed for Smuggling Crocodile, Python Handbags
- IBM Set to Acquire HashiCorp in Possible Mega-Deal, Stock Skyrockets 24% to $6.1 Billion Valuation
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- Stellantis Plans to Lay Off Unspecified Number of Workers at US Factories in Coming Months
- Student Loan Forgiveness Processing for This Group of Borrowers Will Stop Next Week
- Oracle CEO Reveals Plans to Relocate World Headquarters to Nashville, Citing the City’s Reputation as Well-Established Health Center
- Samsung to Implement Six-Day Work Week for Executives Slammed by Critics 'Not Effective'
